GTBP · GT Biopharma, Inc.
$6.47
-0.41 (-5.89%)
At close · Sep 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.43M
Shares
1.80M
Volume · Sep 30
29.76K
Avg daily vol (16 sessions)
145.1K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.47
Open$6.85
Day$6.47–7.02
52W close$5.98–27.00
Avg vol 30d86K
Short int257K · 14.2% float · 1.4d
Short vol43%
Last earningsJun 30, 2021
DataJan 2020–Sep 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Jun 30, 2021
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$4.76M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 1,578.2%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,300.6%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
14.2%
Latest settlement · 1.4 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.3 · calm
Equity put/call 0.53
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−42%
below
Price vs 50-day avg
−14%
below
RSI (14)
43
neutral
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−36%
trailing
YTD return
−67%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
+40% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.22% of float · ▲ +67.0% MoM · 1.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
EPS growth
+4%
Y/Y
Free cash flow
$-12.9M
Quant / Vol
risk profile
Volatility
133%
annualized · 1-yr
Max drawdown
−78%
past year
ATR
14.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−42%
Bearish
Price vs 50-day avg
−14%
Bearish
RSI (14)
43
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $8 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
+40% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
14.22% of float · ▲ +67.0% MoM · 1.4 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
59 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $6
Now $6 · 2%
Range high $27
vs 200-day avg -42%
vs 50-day avg -14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GTBP
this stock
GT Biopharma, Inc.
|
$12.43M | — | — | — | 14.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +15.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -1.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +553.0% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GTBP | -8.9% | -9.5% | -36.1% | -9.5% | -67.0% |
| SPY | -0.7% | +0.1% | +12.2% | -0.6% | +11.8% |
| vs SPY | -8.2% | -9.6% | -48.3% | -8.9% | -78.9% |